Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 3/20 | 0.41 |
| ▸ | NOS3 | P29474 | 2/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12893310 | 0.80 | NOS3 (0.39) | NOS2NOS3NOS1 | |
| SCHEMBL28340170 | 0.78 | NOS3 (0.38) | NOS2NOS3NOS1 | |
| SCHEMBL18519051 | 0.78 | NOS3 (0.38) | NOS2NOS3NOS1KDM4E | |
| SCHEMBL18398216 | 0.78 | NOS2 (0.47) | NOS2NOS3NOS1KDM4E | |
| SCHEMBL22863922 | 0.78 | NOS3 (0.38) | NOS2NOS3NOS1 | |
| SCHEMBL1706079 | 0.78 | NOS3 (0.38) | NOS2NOS3NOS1 | |
| SCHEMBL7222119 | 0.77 | — | — | |
| SCHEMBL17778221 | 0.75 | NOS2 (0.40) | NOS2NOS3NOS1 | |
| SCHEMBL27278600 | 0.75 | GCGR (0.40) | NOS2NOS3 | |
| SCHEMBL1705595 | 0.74 | CCR1 (0.41) | NOS2NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10196399-B2 | Metabotrophic glutamate receptor 5 modulators and methods use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20180037585-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS USE THEREOF | SUNOVION PHARAMCEUTICALS INC. | 2018-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196399-B2 | Metabotrophic glutamate receptor 5 modulators and methods use thereof | GRM5, GRIK5, GRM2 | NOS2 3024/4885NOS3 2487/4885NOS1 3358/4885 |
| US-20180037585-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS USE THEREOF | GRM5, GRIK5, GRM2 | NOS2 3024/4885NOS3 2487/4885NOS1 3358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.